TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07739160: The Efficacy and Safety of HRS-4029 for the Treatment of Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial

Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 340 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07739160 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07739160 Rescue Dossier →